Ogicef T 250mg/31.25mg Injection
Marketer
Logimed Pharma Pvt Ltd
Salt Composition
Ceftriaxone (250mg) + Tazobactum (31.25mg)
Overview Ogicef T 250mg/31.25mg Injection
Cefixime and Sulbactam injection (250mg/31.25mg) is a dual-action antibiotic. It's used to combat diverse bacterial infections by inhibiting microbial proliferation and preventing infection spread. Administration must always be under a doctor's direct supervision. Strictly adhere to the prescribed dosage schedule; complete the full course, regardless of symptom improvement. Premature cessation may compromise its effectiveness. Potential side effects include nausea, vomiting, diarrhea, and digestive upset. Report any worsening side effects immediately to your physician. Seek immediate medical attention for allergic reactions (skin rashes, itching, swelling, breathing difficulties). Inform your doctor of all other medications you're taking, including those for pre-existing conditions. Pregnant or lactating individuals must consult their doctor before use. Alcohol consumption should be avoided due to potential increased drowsiness. While it generally doesn't affect driving ability, refrain from driving if drowsiness or dizziness occurs. Adequate rest, a balanced diet, and sufficient hydration are crucial for optimal recovery. Your doctor may order blood tests and other assessments to monitor treatment efficacy.
Primary Ingredients of Ogicef T 250mg/31.25mg Injection
No text provided. Please provide the text you wish me to rephrase.
Uses of Ogicef T 250mg/31.25mg Injection
Infections caused by bacteria
Major Benefits of Ogicef T 250mg/31.25mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Ogicef T 250mg/31.25mg Injection:
- Diarrhea
- Increased liver enzymes
- Allergic reaction
- Rash
How to use Ogicef T 250mg/31.25mg Injection:
The medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Ogicef T 250mg/31.25mg Injection works:
The injectable formulation Ogicef T (250mg/31.25mg) unites Ceftriaxone, a bacterial cell-wall synthesis inhibitor, with Tazobactum, a beta-lactamase inhibitor. This combination combats bacterial infections; Tazobactum's role is to counteract bacterial resistance mechanisms, thereby optimizing Ceftriaxone's antibiotic effect.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from co-ingesting alcohol and Ogicef T 250mg/31.25mg Injection.
PregnancySAFE IF PRESCRIBED
The injectable medication, Ogicef T 250mg/31.25mg, is typically deemed safe for use in pregnancy. Preclinical trials using animal models have revealed minimal or no harmful effects on fetal development; nevertheless, data from human trials are scarce.
Breast feedingCAUTION
The administration of Ogicef T 250mg/31.25mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's course of treatment and until the medication is fully cleared from her system.
DrivingUNSAFE
The injection Ogicef T 250mg/31.25mg can cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these effects.
KidneyCONSULT YOUR DOCTOR
Data regarding the administration of Ogicef T 250mg/31.25mg Injection to individuals with renal impairment is scarce. Physician consultation is recommended.
LiverCAUTION
The injectable formulation of Ogicef T (250mg/31.25mg) requires careful administration in individuals with advanced hepatic impairment; dosage modification may be necessary. A physician's consultation is advised. Dosage alterations for Ogicef T (250mg/31.25mg) injection are unnecessary in patients exhibiting mild or moderate liver dysfunction.
What if you forget to take Ogicef T 250mg/31.25mg Injection :
Omit a dose of Ogicef T 250mg/31.25mg Injection? Seek your physician's advice.
Facts to Know About Ogicef T 250mg/31.25mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Antimicrobial Agents |
3,018 People bought this recently